AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript
ABCL earnings call for the period ending March 31, 2023.
AbCellera Reports Q1 2023 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies
Check out these compelling opportunities.
AbCellera-backed precision medicine startup Abdera raises $140-million to target tumors
Abdera is developing sophisticated antibodies that can deliver radiopharmaceutical therapies to specific cancer cells like a parcel delivery service
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center...
1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy
These companies are leading the way in using AI in healthcare.
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and...
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando,...